Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, Sestili S, Giannotti F, Vekhoff A, Ledraa T, Legrand O, Lapusan S, Isnard F, Labopin M, Bonnin A, Mediavilla C, Rubio MT, Ruggeri A, Duléry R, Malard F, Mohty M.

Bone Marrow Transplant. 2019 Oct 31. doi: 10.1038/s41409-019-0726-7. [Epub ahead of print]

PMID:
31673080
2.

Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.

Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E.

Bone Marrow Transplant. 2019 Sep 25. doi: 10.1038/s41409-019-0690-2. [Epub ahead of print]

PMID:
31554931
3.

Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation.

Mohty R, Brissot E, Battipaglia G, Ruggeri A, Dulery R, Bonnin A, Médiavilla C, Sestili S, Belhocine R, Vekhoff A, Ledraa T, Lapusan CS, Adaeva R, Isnard F, Legrand O, Mohty M, Malard F.

Br J Haematol. 2019 Nov;187(3):e64-e68. doi: 10.1111/bjh.16189. Epub 2019 Sep 5. No abstract available.

PMID:
31487392
4.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24.

PMID:
31339826
5.

Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.

Stocker N, Duléry R, Battipaglia G, Brissot E, Médiavilla C, Sestili S, Paviglianiti A, Ledraa T, Mohty R, Bazarbachi A, Belhocine R, Vekhoff A, Ruggeri A, Mohty M, Malard F.

Eur J Haematol. 2019 Jul;103(1):10-17. doi: 10.1111/ejh.13233. Epub 2019 May 14.

PMID:
30958904
6.

Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.

Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415. doi: 10.1016/j.bbmt.2019.02.025. Epub 2019 Mar 11.

PMID:
30871978
7.

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1.

8.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

9.

Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study.

Lehrer J, Brissot E, Ruggeri A, Dulery R, Vekhoff A, Battipaglia G, Giannotti F, Fernandez C, Mohty M, Antignac M.

Bone Marrow Transplant. 2018 Feb;53(2):231-233. doi: 10.1038/bmt.2017.233. Epub 2017 Nov 20. No abstract available.

PMID:
29155420
10.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10.

PMID:
28395585
11.

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A.

Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.

12.

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.

Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M.

Transpl Infect Dis. 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25.

PMID:
26354178
13.

Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation.

Battipaglia G, Ruggeri A, Brissot E, Mamez AC, Malard F, Belhocine R, Vekhoff A, Giannotti F, Ledraa T, Labopin M, Rubio MT, Mohty M.

Bone Marrow Transplant. 2015 Dec;50(12):1574-7. doi: 10.1038/bmt.2015.182. Epub 2015 Aug 17. No abstract available.

PMID:
26281029
14.

Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A.

Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7.

15.

Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature.

Guitard J, Angoulvant A, Letscher-Bru V, L'Ollivier C, Cornet M, Dalle F, Grenouillet F, Lacroix C, Vekhoff A, Maury E, Caillot D, Charles PE, Pili-Floury S, Herbrecht R, Raffoux E, Brethon B, Hennequin C.

Med Mycol. 2013 Nov;51(8):795-9. doi: 10.3109/13693786.2013.807444. Epub 2013 Jul 16. Review.

PMID:
23855412
16.

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.

Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P; European APL group.

Am J Hematol. 2013 Jul;88(7):556-9. doi: 10.1002/ajh.23451. Epub 2013 Jun 12.

17.

Double-delayed intensification paediatric protocol without radiotherapy is an efficient treatment in adult lymphoblastic lymphoma.

Corre E, Marjanovic Z, Lapusan S, Vekhoff A, Hirsch P, Marie JP, Legrand O.

Hematol Oncol. 2012 Dec;30(4):206-9. doi: 10.1002/hon.2007. Epub 2012 Jan 23.

PMID:
22271176
18.

Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients.

Bergeron A, Porcher R, Menotti J, Poirot JL, Chagnon K, Vekhoff A, Cornet M, Isnard F, Raffoux E, Brethon B, Lacroix C, Touratier S, Latgé JP, Bouges-Michel C, Tazi A, Derouin F, Ribaud P, Sulahian A.

J Clin Microbiol. 2012 Mar;50(3):823-30. doi: 10.1128/JCM.00750-11. Epub 2011 Dec 14.

19.

The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies.

Bergeron A, Porcher R, Sulahian A, de Bazelaire C, Chagnon K, Raffoux E, Vekhoff A, Cornet M, Isnard F, Brethon B, Lacroix C, Poirot JL, Bouges C, Derouin F, Tazi A, Ribaud P.

Blood. 2012 Feb 23;119(8):1831-7; quiz 1956. doi: 10.1182/blood-2011-04-351601. Epub 2011 Oct 18.

PMID:
22010103
20.

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, Meurice G, Oréar C, Preudhomme C, Gardin C, Ades L, Fontenay M, Fenaux P, Droin N, Solary E; Groupe Francophone des Myélodysplasies.

Blood. 2011 Oct 6;118(14):3824-31. doi: 10.1182/blood-2011-05-352039. Epub 2011 Aug 9.

PMID:
21828134
21.

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP.

Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26.

PMID:
21519855
22.

Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.

Hivert B, Tamburini J, Vekhoff A, Tournilhac O, Leblond V, Morel P.

Haematologica. 2011 May;96(5):785-8. doi: 10.3324/haematol.2010.029140. Epub 2011 Mar 10. No abstract available.

23.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

24.

A retrospective series of gut aspergillosis in haematology patients.

Kazan E, Maertens J, Herbrecht R, Weisser M, Gachot B, Vekhoff A, Caillot D, Raffoux E, Fagot T, Reman O, Isnard F, Thiebaut A, Bretagne S, Cordonnier C.

Clin Microbiol Infect. 2011 Apr;17(4):588-94. doi: 10.1111/j.1469-0691.2010.03310.x.

25.

Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol.

Haïat S, Marjanovic Z, Lapusan S, Vekhoff A, Rio B, Corre E, Dimicoli S, Hirsch P, Marie JP, Legrand O.

Leuk Res. 2011 Jan;35(1):66-72. doi: 10.1016/j.leukres.2010.04.002.

PMID:
20434771
26.

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study.

Michallet M, Tulliez M, Corm S, Gardembas M, Huguet F, Oukessou A, Bregman B, Vekhoff A, Ghomari K, Cambier N, Guerci-Bresler A.

Curr Med Res Opin. 2010 Feb;26(2):307-17. doi: 10.1185/03007990903479299.

PMID:
19961284
27.

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M.

Clin Infect Dis. 2009 Apr 15;48(8):1042-51. doi: 10.1086/597395.

PMID:
19281327
28.

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.

Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerri L.

Blood. 2009 Mar 19;113(12):2765-3775. doi: 10.1182/blood-2008-07-168096. Epub 2008 Dec 18.

PMID:
19096012
29.

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, Mahe B, Sanhes L, Stamatoullas A, Vey N, Aouba A, Slama B, Quesnel B, Vekhoff A, Sotto JJ, Vassilief D, Al-Nawakil C, Fenaux P, Dreyfus F, Bouscary D; Groupe Francophone des Myélodysplasies, GFM.

Leuk Res. 2009 Apr;33(4):547-50. doi: 10.1016/j.leukres.2008.06.005. Epub 2008 Jul 21. No abstract available.

PMID:
18640718
30.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.

Blood. 2008 Aug 15;112(4):999-1004. doi: 10.1182/blood-2008-01-131029. Epub 2008 May 7.

PMID:
18463354
31.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P.

Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1.

PMID:
17975017
32.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.

PMID:
17116939
33.

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP.

Br J Cancer. 2006 Aug 7;95(3):253-9. Epub 2006 Jul 18.

34.

Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).

Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P.

Leukemia. 2006 May;20(5):905-7. No abstract available.

PMID:
16541143
35.
36.

Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.

Thomas X, Le Q, Botton Sd, Raffoux E, Chelghoum Y, Pautas C, Dreyfus F, Dhedin N, Vekhoff A, Troncy J, Pigneux A, Revel Td, Reman O, Travade P, Thiebaut A, Guerci A, Elhamri M, Fenaux P, Dombret H, Michallet M.

Leuk Lymphoma. 2005 Jul;46(7):1007-16.

PMID:
16019551
37.

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.

Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H; European APL Group.

Leukemia. 2005 Jul;19(7):1153-60.

PMID:
15889156
38.

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.

Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P.

Blood. 2004 Jul 15;104(2):321-7. Epub 2004 Mar 30.

PMID:
15054036
39.

Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.

Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, Ferrant A, Sanz M, Fey M, Chomienne C, Chevret S, Degos L, Fenaux P; European APL group experience.

Leukemia. 2003 Aug;17(8):1600-4.

PMID:
12886249
40.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.

de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Fey M, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P; European APL group.

Leukemia. 2003 Feb;17(2):339-42.

PMID:
12592333
41.

[Therapeutic impact of streptococcal and enterococcal bacteremia in hematology patients].

Ombandza-Moussa E, Schlegel L, Vekhoff A, Gerbal R, Marie JP, Bouvet A.

Pathol Biol (Paris). 2002 Apr;50(3):169-77. French.

PMID:
11980330
42.

All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.

Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E.

Hematol J. 2002;3(1):49-55.

PMID:
11960396
43.

A case of disseminated aspergillosis with thyroid involvement.

Cornet M, Ugo V, Lefort E, Molina T, James JM, Vekhoff A, Audouin J, Marie JP, Bouvet A.

Eur J Clin Microbiol Infect Dis. 2001 May;20(5):358-9. No abstract available.

PMID:
11453600
44.

Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.

Thomas X, Cambier N, Taksin AL, Reman O, Vekhoff A, Pautas C, Leblond V, Soler-Michel P, Ecstein-Fraïssé E, Archimbaud E.

Leuk Res. 2000 Nov;24(11):957-63.

PMID:
11086179
45.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.

Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P.

Leukemia. 2000 Jun;14(6):1006-13.

46.

Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years.

Lévy V, Marjanovic Z, Vekhoff A, Belhocine R, Marie JP, Delmer A, Ajchenbaum-Cymbalista F, Zittoun R, Rio B.

Am J Hematol. 2000 Jul;64(3):232-3. No abstract available.

47.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).

Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E.

Leukemia. 1999 Aug;13(8):1214-20.

48.

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.

Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, Baudard M, Legrand O, Rio B, Delmer A, Zittoun R.

Support Care Cancer. 1999 Mar;7(2):89-94.

PMID:
10089089
49.

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.

Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H.

J Antimicrob Chemother. 1998 Jun;41 Suppl D:57-64.

PMID:
9688452
50.

Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects.

Legrand O, Vekhoff A, Marie JP, Zittoun R, Delmer A.

Br J Haematol. 1997 Oct;99(1):165-7.

PMID:
9359518

Supplemental Content

Loading ...
Support Center